YahooAugust 6, 2026 at 9:03 PM NY2 Months Ago
CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
